click below
click below
Normal Size Small Size show me how
Colorectal Carcinoma
Pharmacology for colorectal carcinoma
| Question | Answer |
|---|---|
| What classes of chemotherapeutic agents are available for colon cancer? | 1. DNA-damaging agents 2. Anti-metabolites 3. Molecularly targeted drugs (cancer specific) |
| What DNA damaging agents are used to treat colon cancer? | 1. Platinum compounds 2. Topoisomerase inhibitors |
| What is the formula for colon cancer chemotherapy? | Antimetabolite + (Platinum compound OR Topo-I inhibitor) +/- Molecular-targeting agent |
| Which pyrimidine antimetabolite is often used for colon cancer? | 5-flourouracil |
| In general, how do antimetabolite drugs work? | They inhibit chemicals that are part of normal metabolism, thus leading to toxic effects on cells, such as halting cell growth and division. |
| What is the MOA of 5-FU? | It inhibits thymidylate synthase (FdUMP); interferes with RNA synthesis (FUTP); and has some effects on DNA synthesis (FdUTP). |
| This drug, which is used in combination with methotrexate, is also used in combination with 5-FU. | Leucovorin |
| An orally stable prodrug that is enzymatically converted to 5-FU within tumors? | Capecitabine (Xeloda) |
| Pros and cons of using Capecitabine over 5-FU | Pro: Orally active (no need for continuous I.V. infusions) Con: Costs $3600/month (vs $100/month) |
| Deficiency of this enzyme will increase the risk for 5-FU toxicity in 5-FU users, due to inability to metabolize 5-FU. | Dihydropyrimidine Dehydrogenase (DPD) |
| Fully reduced folate that potentiates cell killing by 5-FU. | Leucovorin (Folinic acid) |
| How do colorectal tumors become resistant to 5-FU? | They overexpress thymidylate synthase (TS) or mutate it to a resistant form. |
| Platinum compounds | Cisplatin, Carboplatin, Oxaliplatin |
| MOA of Oxaliplatin | 1. Intra-chain cross-linking of DNA (N7 and 06 of guanine are susceptible) 2. Generation of free radicals 3. Inhibits dTTP synthesis (needed for synthesis of DNA) by blocking TS |
| Toxicities of Oxaliplatin | Hearing loss; Bone marrow toxicity; Mutagenic; Peripheral neuropathy |
| MOA of Irinotecan (aka CPT-11 and Camptosar) | Inhibits topoisomerase I |
| Topoisomerases | Enzymes that unwind DNA, in order for DNA to control the synthesis of proteins, and to facilitate DNA replication. |
| Ironotecan is a synthetic analog of this natural product | Camptothecin |
| Side effects of Irinotecan | Severe diarrhea and immunosuppression due to neutropenia |
| Patients with this enzyme deficiency display greater toxicity with Irinotecan | UGT1A1 enzyme |
| What is CAPOX? | Colon cancer regime of Capecitabine plus Oxaliplatin |
| What is FOLFOX? | Colon cancer regime of Oxaliplatin, Leucovorin, and 5-FU |
| Monoclonal antibodies against epidermal growth factor receptor (EGFR) that cause T-cell mediated killing and receptor blockade | Cetuximab (Erbitux) and Panitumumab |
| Monoclonal antibodies against vascular endothelial growth factor (VEGF); blocks angiogenesis | Bevicizumab/Avastin |
| Blockade of the EGFR receptor blocks binding of this hormone | Growth factor; results in inhibition of cell growth and leads to cell death |
| Over-expession of this receptor is found in many human cancers (~75%) including those of the colon and rectum | EGFR |
| Is indicated for treatment of Stage IV (metastatic) colorectal cancer after failure of Irinotecan | Erbitux/Cetuximab |
| Side effects of Erbitux/Cetuximab | Rash, infusion reaction, darrhea, and rare lung toxicity |
| Avastin/Bevacizumab is approved for what 3 leading causes of cancer death | 1. Metastatic colorectal cancer 2. Advanced non-squamous, non-small cell lung cancer 3. Metastatic HER2-negative breast cancer |
| Side effects of Avastin/Bevacizumab | G.I. perforation; wound healing complications; hemorrhage; non-GI fistula formation; arterial thromboembolic events; neutropenia and infection; nephrotic syndrome, CHF; hypertension; proteinuria; headache |